GI Medical Oncologist at BC Cancer, Associate Professor at The University of British Columbia, Senior Investigator at the Canadian Cancer Trials Group (CCTG)
This is an absolutely outstanding review on the management of patients with metastatic gastric cancer.
I may have posted about this review before but it is so good that it deserves another round of applause... Thanks @KlempnerSam@YJanjigianMD@amalsargsyan and all the other co-authors I could not find on X...
Sorry AI, I love you but you are just not there yet. True content experts writing a practical review still beat you easily.
This should be a required read for all who take care of patients with gastric cancer.
https://t.co/5eCIbBwK7G
@GillSharlene@CDNCancerTrials@JeanneTie Great to hear from @JeanneTie and look for new opportunities to work together with @GICancer. Also excited to plan the BATTMAN trials upcoming launch in Australia and New Zealand. Botensilimab plus balstilimab in #mcrc
🌐 BATTMAN trial begins in MSS metastatic colorectal cancer
On April 1, 2026, Agenus announced that the first patient has been enrolled in the phase III BATTMAN trial.
BATTMAN is a global, randomized phase III study evaluating botensilimab + balstilimab vs best supportive care in patients with refractory, unresectable MSS metastatic colorectal cancer.
The trial is being conducted across international sites and represents a potential registrational study in this setting.
@Agenus_Bio@oncodaily@jonathanloree@garo_armen
📎https://t.co/beAJM9r3Zm
#OncoDaily #GIOncology #ColorectalCancer #Immunotherapy #ClinicalTrials
Sharing the final publication and schema! @NANETS1 Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors https://t.co/UDLJ8ZI75f
@OHSUKnight study showed standard dose (35mg/m2 bid) Trifluridine (Lonsurf) wk 1, 3 and 5 of #radiation for stage 2/3 #rectalcancer was safe with TNT. 56% of patients did Watch and Wait.
➡️New option for patients with 5-FU toxicity/contraindications❓
https://t.co/YriIxXipl6
Check out our new @NANETS Guidelines for Stage I-III Rectal NETs! Big updates in:
- staging with MRI & PET Dotatate
- advanced excision for < vs. >10 mm tumors
- management of R1 excision
- surgery
- follow-up
@AmanChauhanMD@OncoThor@FlavioRochaMD
https://t.co/UDLJ8ZI75f
Congrats @RobertoFedrigo on your new manuscript on treatment attrition in NETs! Shows how many patients never reach later lines of therapy. Important context as we interpret NETTER-2 and debate earlier PRRT use.
https://t.co/LYDvp8lli1
#NETs#PRRT#NETTER2#oncology
How would you prefer to be screened for colorectal cancer? 🩺
We’re surveying people to better understand preferences — including whether blood-based tests could reduce barriers. Please retweet &
Share your voice: https://t.co/KYlF6TgWFq
@BCCancer@bccancerfdn@coloncanada
Applications are being accepted for the #CCTG 2026-2027 New Investigator Cancer Trials Practicum - a training program that enables the brightest new Canadian oncology researchers to acquire training & experience in clinical trial conduct. How to apply: https://t.co/XKoxykJcCr
AI meets digital pathology! 🔬 We used machine learning on whole-slide images of neuroendocrine tumors to classify grade, differentiation & prognosis.
✍ Authors: Amir Hadjifaradji et al. @jonathanloree@BCCancer@bccancerfdn
🌻 Read in @Cancers_MDPI
https://t.co/u5MhkS7gYD
A nice retrospective study looking at chemo doublets in biliary tract cancer. "FOLFOX Versus FOLFIRI as Second‐Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study - Pircher - 2026" https://t.co/FPzT3MMXJO
Results from DYNAMIC-III RCT of ctDNA-guided adjuvant tx in stage III colon cancer in Nature Med.
🙏 to pts, providers & @JeanneTie
🇨🇦🇦🇺 @CDNCancerTrials & @GICancer Collab
#ESMO2025 Presidential | Supported by @CIHR_IRSC & @cancersociety in 🇨🇦
🔗 https://t.co/8DcYxgy2P3